DNAJB7

Summary

DNAJB7 (DnaJ heat shock protein family (Hsp40) member B7, HGNC:24986) is a protein-coding gene on chromosome 22q13.2, encoding DnaJ homolog subfamily B member 7 (Q7Z6W7). Probably acts as a co-chaperone.

The protein encoded by this intronless gene belongs to the evolutionarily conserved DNAJ/HSP40 family of proteins, which regulate molecular chaperone activity by stimulating ATPase activity. DNAJ proteins may have up to 3 distinct domains: a conserved 70-amino acid J domain, usually at the N terminus; a glycine/phenylalanine (G/F)-rich region; and a cysteine-rich domain containing 4 motifs resembling a zinc finger domain.

Source: NCBI Gene 150353 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 76 total — 3 pathogenic
• MANE Select transcript: NM_145174

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24986
Approved symbol	DNAJB7
Name	DnaJ heat shock protein family (Hsp40) member B7
Location	22q13.2
Locus type	gene with protein product
Status	Approved
Aliases	HSC3
Ensembl gene	ENSG00000172404
Ensembl biotype	protein_coding
OMIM	611336
Entrez	150353

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000307221

RefSeq mRNA: 1 — MANE Select: NM_145174 NM_145174

CCDS: CCDS14008

Canonical transcript exons

ENST00000307221 — 1 exons

Exon	Start	End
ENSE00001267800	40859549	40862113

Expression profiles

Bgee: expression breadth ubiquitous, 127 present calls, max score 85.64.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0255 / max 21.6521, expressed in 4 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
194334	0.0255	4

Top tissues by expression

217 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.64	gold quality
right testis	UBERON:0004534	78.05	gold quality
left testis	UBERON:0004533	77.20	gold quality
testis	UBERON:0000473	74.27	gold quality
cortical plate	UBERON:0005343	67.00	gold quality
ganglionic eminence	UBERON:0004023	62.35	gold quality
buccal mucosa cell	CL:0002336	60.03	silver quality
jejunal mucosa	UBERON:0000399	58.60	silver quality
hindlimb stylopod muscle	UBERON:0004252	55.87	gold quality
cerebellar cortex	UBERON:0002129	55.23	gold quality
cerebellar hemisphere	UBERON:0002245	55.15	gold quality
ventricular zone	UBERON:0003053	54.77	silver quality
corpus epididymis	UBERON:0004359	54.77	silver quality
bone marrow cell	CL:0002092	54.71	gold quality
mucosa of transverse colon	UBERON:0004991	54.53	gold quality
right hemisphere of cerebellum	UBERON:0014890	54.44	gold quality
caput epididymis	UBERON:0004358	54.17	silver quality
gastrocnemius	UBERON:0001388	54.13	gold quality
muscle of leg	UBERON:0001383	54.04	gold quality
cerebellum	UBERON:0002037	54.04	gold quality
duodenum	UBERON:0002114	53.81	gold quality
cerebellar vermis	UBERON:0004720	52.48	gold quality
colonic epithelium	UBERON:0000397	51.24	gold quality
prefrontal cortex	UBERON:0000451	50.76	gold quality
jejunum	UBERON:0002115	50.26	silver quality
right ovary	UBERON:0002118	49.48	gold quality
right uterine tube	UBERON:0001302	49.44	gold quality
cauda epididymis	UBERON:0004360	48.88	gold quality
right lobe of thyroid gland	UBERON:0001119	48.54	gold quality
left ovary	UBERON:0002119	48.11	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-CURD-10	no	10.06
E-ANND-3	no	2.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

69 targeting DNAJB7, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-512-3P	99.97	67.35	1049
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-5682	99.89	72.56	1005
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-576-5P	99.84	70.46	2582
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-1283	99.69	72.42	3009

Cross-species orthologs

16 orthologs

Organism	Symbol	Gene ID
danio_rerio	dnajb6b	ENSDARG00000020953
danio_rerio	dnajb1b	ENSDARG00000041394
danio_rerio	dnajc18	ENSDARG00000056005
danio_rerio	dnajb1a	ENSDARG00000099383
mus_musculus	Dnajb7	ENSMUSG00000047108
rattus_norvegicus	Dnajb7	ENSRNOG00000019187
drosophila_melanogaster	CG2887	FBGN0030207
drosophila_melanogaster	CG5001	FBGN0031322
drosophila_melanogaster	mrj	FBGN0034091
drosophila_melanogaster	CG3061	FBGN0038195
drosophila_melanogaster	CG30156	FBGN0050156
drosophila_melanogaster	DnaJ-1	FBGN0263106
caenorhabditis_elegans		WBGENE00001019
caenorhabditis_elegans		WBGENE00001031
caenorhabditis_elegans		WBGENE00001042
caenorhabditis_elegans		WBGENE00001044

Paralogs (11): DNAJB11 (ENSG00000090520), DNAJB6 (ENSG00000105993), DNAJB9 (ENSG00000128590), DNAJB1 (ENSG00000132002), DNAJB2 (ENSG00000135924), DNAJB5 (ENSG00000137094), DNAJB12 (ENSG00000148719), DNAJB4 (ENSG00000162616), DNAJB14 (ENSG00000164031), DNAJB8 (ENSG00000179407), DNAJB13 (ENSG00000187726)

Protein

Protein identifiers

DnaJ homolog subfamily B member 7 — Q7Z6W7 (reviewed: Q7Z6W7)

All UniProt accessions (1): Q7Z6W7

UniProt curated annotations — full annotation on UniProt →

Function. Probably acts as a co-chaperone.

RefSeq proteins (1): NP_660157* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001623	DnaJ_domain	Domain
IPR018253	DnaJ_domain_CS	Conserved_site
IPR036869	J_dom_sf	Homologous_superfamily
IPR043183	DNJB2/6-like	Family

Pfam: PF00226

UniProt features (5 total): chain 1, domain 1, region of interest 1, compositionally biased region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7Z6W7-F1	59.38	0.08

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 40 (showing top): FOXD3_01, NKX62_Q2, GOBP_PROTEIN_MATURATION, GOBP_PROTEIN_FOLDING, AGCATTA_MIR155, TGGAAA_NFAT_Q4_01, chr22q13, GOMF_HEAT_SHOCK_PROTEIN_BINDING, GOMF_UNFOLDED_PROTEIN_BINDING, GOMF_PROTEIN_FOLDING_CHAPERONE_BINDING, GOMF_HSP70_PROTEIN_BINDING, ZWANG_DOWN_BY_2ND_EGF_PULSE, GOMF_PROTEIN_FOLDING_CHAPERONE, ZNF85_TARGET_GENES, MIR1283

GO Biological Process (2): protein folding (GO:0006457), obsolete chaperone-mediated protein folding (GO:0061077)

GO Molecular Function (4): Hsp70 protein binding (GO:0030544), protein folding chaperone (GO:0044183), obsolete unfolded protein binding (GO:0051082), protein-folding chaperone binding (GO:0051087)

GO Cellular Component (2): nucleus (GO:0005634), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular process	1
protein maturation	1
heat shock protein binding	1
protein-folding chaperone binding	1
molecular_function	1
protein folding	1
protein binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

2144 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DNAJB7	TECR	Q9NZ01	882
DNAJB7	CA9	Q16790	761
DNAJB7	MAU2	Q9Y6X3	716
DNAJB7	ONECUT3	O60422	542
DNAJB7	FN1	P02751	535
DNAJB7	CASP3	P42574	474
DNAJB7	ANXA5	P08758	452
DNAJB7	HMOX1	P09601	445
DNAJB7	GAPDH	P00354	437
DNAJB7	TBCCD1	Q9NVR7	433
DNAJB7	MTRNR2L6	P0CJ73	420
DNAJB7	CDH1	P12830	418
DNAJB7	GFOD2	Q3B7J2	409
DNAJB7	EGFR	P00533	406
DNAJB7	AKT1	P31749	403

IntAct

3 interactions, top by confidence:

A	B	Type	Score
DNAJB7	SRPK2	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
DNAJB7	PPP2R5D	psi-mi:“MI:0914”(association)	0.350

BioGRID (36): DNAJB7 (Affinity Capture-Western), DNAJB7 (Affinity Capture-Western), DNAJB7 (Reconstituted Complex), DNAJB7 (Affinity Capture-MS), FKBP8 (Affinity Capture-MS), DNAJB1 (Affinity Capture-MS), HNRNPM (Affinity Capture-MS), RPL26 (Affinity Capture-MS), RPL4 (Affinity Capture-MS), RPL18 (Affinity Capture-MS), RPLP0 (Affinity Capture-MS), DNAJC7 (Affinity Capture-MS), GRPEL1 (Affinity Capture-MS), BAG2 (Affinity Capture-MS), CMAS (Affinity Capture-MS)

ESM2 similar proteins: C0HK94, C0HK95, E9PV24, J7M3T1, J7M799, M9MRD1, O13858, O54946, O75190, P02671, P02672, P0CU45, P0CU46, P0CU47, P0CU48, P0CU50, P14448, P20240, P30933, P36228, P46335, P78890, P87346, Q04757, Q09231, Q24546, Q4WUL0, Q4X212, Q55FC2, Q55FC3, Q55FC4, Q55FC5, Q5F3Z5, Q5R8H0, Q6AYU3, Q6CVS3, Q6FJC7, Q6FX33, Q7Z6W7, Q90501

Diamond homologs: A0A0D1E2P6, A0A0P0VG31, A1BHL1, A1V9Q3, A3MA88, A4SFR5, A5EYE5, A5IIT4, A5ITA7, A6LJ63, A6QHC2, A6U251, A7X2Y0, A8EXP6, A8GMF8, A8GV67, A9IGC5, B0B7R0, B0BBX5, B0TYF3, B0VA24, B0VQ00, B1LCI2, B1YKT0, B2I2G6, B3CP03, B3EE31, B3QPW8, B4S9D0, B7GV08, B7I2B2, B7IFE0, B8DQW8, B9E6X0, B9KAB9, C4L424, O35723, O54946, O75190, O84345

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

76 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	63
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
2424165	NC_000022.10:g.(?41074407)(41489122_?)del	Pathogenic
3062459	GRCh37/hg19 22q13.1-13.2(chr22:39935185-41752098)x1	Pathogenic
57634	GRCh38/hg38 22q13.2(chr22:40832364-41076954)x1	Pathogenic

SpliceAI

156 predictions. Top by Δscore:

Variant	Effect	Δscore
22:40861732:AAGCC:A	donor_gain	0.9800
22:40861726:A:T	donor_gain	0.9700
22:40861734:GCC:G	donor_gain	0.9000
22:40861774:TTTA:T	donor_gain	0.8700
22:40861725:G:GT	donor_gain	0.8500
22:40861847:C:G	donor_gain	0.8000
22:40861730:TG:T	donor_gain	0.7900
22:40861666:TGAA:T	donor_gain	0.7600
22:40861836:G:GG	donor_gain	0.7200
22:40861617:GGA:G	acceptor_gain	0.7100
22:40861777:A:AT	donor_gain	0.7100
22:40861731:GAAGC:G	donor_gain	0.7000
22:40861612:CCATA:C	acceptor_loss	0.6600
22:40861613:CATAG:C	acceptor_loss	0.6600
22:40861615:TA:T	acceptor_loss	0.6600
22:40861617:G:GC	acceptor_loss	0.6600
22:40861728:T:G	donor_gain	0.6600
22:40861642:TCCTC:T	donor_gain	0.6500
22:40861616:A:AG	acceptor_gain	0.6300
22:40861617:G:GG	acceptor_gain	0.6300
22:40861731:G:GT	donor_gain	0.6300
22:40861835:C:CG	donor_gain	0.6300
22:40861679:G:GT	donor_gain	0.6100
22:40861601:T:TA	acceptor_loss	0.6000
22:40861608:GTTTC:G	acceptor_loss	0.5600
22:40861618:G:T	acceptor_loss	0.5600
22:40861760:G:GT	donor_gain	0.5600
22:40861736:C:CG	donor_gain	0.5500
22:40861737:G:GG	donor_gain	0.5500
22:40861657:T:G	acceptor_gain	0.5400

AlphaMissense

2066 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
22:40861857:G:C	F46L	0.968
22:40861857:G:T	F46L	0.968
22:40861859:A:G	F46L	0.968
22:40861828:A:G	L56S	0.950
22:40861841:C:G	A52P	0.931
22:40861902:G:C	H31Q	0.923
22:40861902:G:T	H31Q	0.923
22:40861858:A:G	F46S	0.905
22:40861915:G:T	A27E	0.905
22:40861810:C:G	R62P	0.904
22:40861840:G:T	A52E	0.903
22:40861907:A:G	W30R	0.901
22:40861907:A:T	W30R	0.901
22:40861871:C:G	A42P	0.898
22:40861893:T:A	K34N	0.889
22:40861893:T:G	K34N	0.889
22:40861847:C:G	A50P	0.880
22:40861904:G:C	H31D	0.880
22:40861935:T:A	K20N	0.877
22:40861935:T:G	K20N	0.877
22:40861854:T:A	K47N	0.876
22:40861854:T:G	K47N	0.876
22:40861931:C:G	A22P	0.876
22:40861928:A:C	Y23D	0.855
22:40861731:G:C	F88L	0.845
22:40861731:G:T	F88L	0.845
22:40861733:A:G	F88L	0.845
22:40861912:A:G	L28P	0.844
22:40861704:A:C	F97L	0.838
22:40861704:A:T	F97L	0.838

dbSNP variants (sampled 300 via entrez): RS1002902048 (22:40862696 T>A,C,G), RS1003247107 (22:40861521 T>A,C), RS1004093756 (22:40863122 T>C), RS1004936576 (22:40860688 T>C), RS1005250864 (22:40861995 G>GT), RS1005595042 (22:40864000 A>G), RS1006105238 (22:40860717 A>C,G,T), RS1006184349 (22:40861766 C>A,T), RS1006349553 (22:40862205 G>A,T), RS1007262838 (22:40859871 T>G), RS1007344841 (22:40860935 A>G,T), RS1007762186 (22:40863025 A>C,G), RS1008124783 (22:40863390 T>A,G), RS1009776151 (22:40859969 G>T), RS1010000073 (22:40864015 C>G,T)

Disease associations

OMIM: gene MIM:611336 | disease phenotypes: MIM:613684

GenCC curated gene-disease

Mondo (2): kidney disorder (MONDO:0005240), Rubinstein-Taybi syndrome due to EP300 haploinsufficiency (MONDO:0013364)

Orphanet (2): Rubinstein-Taybi syndrome due to EP300 haploinsufficiency (Orphanet:353284), Rubinstein-Taybi syndrome (Orphanet:783)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004521_42	Autism spectrum disorder or schizophrenia	1.000000e-08
GCST004521_55	Autism spectrum disorder or schizophrenia	9.000000e-09
GCST008103_42	Bipolar disorder	2.000000e-07
GCST008115_35	Bipolar I disorder	3.000000e-07

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009963	bipolar I disorder

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D007674	Kidney Diseases	C12.050.351.968.419; C12.200.777.419; C12.950.419

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

8 total (human), top 8 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
perfluorooctanoic acid	increases expression	1
coumarin	increases phosphorylation	1
CGP 52608	affects binding, increases reaction	1
perfluoro-n-nonanoic acid	increases expression	1
Sunitinib	increases expression	1
Amiodarone	increases expression	1
8-Bromo Cyclic Adenosine Monophosphate	increases expression	1
tert-Butylhydroperoxide	decreases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00067990	PHASE4	COMPLETED	Angiotensin II Blockade for Chronic Allograft Nephropathy
NCT00117078	PHASE4	COMPLETED	Aranesp® Monthly Preference Study - 2
NCT00117130	PHASE4	COMPLETED	Study to Evaluate Effectiveness of Aranesp®
NCT00132431	PHASE4	COMPLETED	START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism
NCT00140985	PHASE4	COMPLETED	Antiproteinuric Efficacy of Losartan Potassium in Patients With Non-Diabetic Proteinuric Renal Diseases (0954-213)
NCT00246129	PHASE4	COMPLETED	CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation
NCT00275535	PHASE4	COMPLETED	The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
NCT00282217	PHASE4	COMPLETED	Study Evaluating Sirolimus in the Treatment of Kidney Transplant
NCT00289614	PHASE4	COMPLETED	Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
NCT00290069	PHASE4	UNKNOWN	Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA)
NCT00338468	PHASE4	TERMINATED	A Study to Assess Disability in Anemic Elderly Patients With Kidney Disease Receiving PROCRIT (Epoetin Alfa)
NCT00368901	PHASE4	COMPLETED	STAAR-2 Clinical Study
NCT00369733	PHASE4	COMPLETED	STAAR-3 Clinical Study
NCT00369772	PHASE4	COMPLETED	STAAR-1 Clinical Study
NCT00379899	PHASE4	COMPLETED	ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis
NCT00443508	PHASE4	UNKNOWN	Reduction or Discontinuation of CNI’s With Conversion to Everolimus-Based Immunosuppresion
NCT00452478	PHASE4	TERMINATED	Conversion From Standard Phosphate Binder Therapy to Fosrenol® (Lanthanum Carbonate) in Chronic Kidney Disease Stage 5
NCT00492518	PHASE4	COMPLETED	Acetylcysteine, Theophylline, and a Combination of Both in the Prophylaxis of Contrast-Induced Nephropathy
NCT00505102	PHASE4	UNKNOWN	Safe Renal Function In Long Term Heart Transplanted Patients
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00688480	PHASE4	COMPLETED	Do Xanthine Oxidase Inhibitors Reduce Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Cardiovascular Patients With Renal Dysfunction?
NCT00863707	PHASE4	COMPLETED	A Study of the Safety and Tolerance of Regadenoson in Subjects With Renal Impairment
NCT01101698	PHASE4	UNKNOWN	Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients
NCT01150201	PHASE4	COMPLETED	Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease
NCT01155141	PHASE4	COMPLETED	Idiopathic Focal Segmental Glomerulosclerosis (FSGS) and Treatment With ACTH
NCT01228279	PHASE4	COMPLETED	Sympathetic Activity in Patients With End-stage Renal Disease on Peritoneal Dialysis
NCT01334333	PHASE4	COMPLETED	Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients
NCT01437943	PHASE4	TERMINATED	Effect of Short Term Aliskiren Treatment in Kidney Transplant Patients
NCT01545479	PHASE4	COMPLETED	Increased Renal Oxygenation and Angiotensin Converting Enzyme Inhibition
NCT01614431	PHASE4	COMPLETED	N Acetyl Cysteine for Cystinosis Patients
NCT01631149	PHASE4	COMPLETED	Effect of Deep BLock on Intraoperative Surgical Conditions
NCT01722513	PHASE4	UNKNOWN	Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
NCT01985360	PHASE4	COMPLETED	ISCHEMIA-Chronic Kidney Disease Trial
NCT02311010	PHASE4	UNKNOWN	Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
NCT02413073	PHASE4	COMPLETED	Whole Body Vibration in Kidney Disease
NCT02444013	PHASE4	UNKNOWN	Folic Acid for Prevention of Contrast Induced Nephropathy
NCT02663713	PHASE4	COMPLETED	A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction
NCT02707809	PHASE4	COMPLETED	Effects of Dexmedetomidine on Microcirculation of Kidney Transplant Recipient
NCT02761577	PHASE4	COMPLETED	A Prospective Study on Incidence and Prevention of Contrast-induced Nephropathy in Croatia
NCT03029351	PHASE4	TERMINATED	GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes